Table 1.

Summary of all cases of MEWDS following vaccination.

Study	Vaccine name	Age	Gender	Time from vaccination (days)	Vaccine type	Comorbidities	Presenting VA in affected eye (Snellen)	Vision at last visit in the affected eye	Intervention	Time until resolution (weeks)
Baglivo et al.[10]	Hepatitis B booster 3rd dose	23	F	1	Recombinant vaccines	None	20/200	Undisclosed-“recovery of vision”	None	12
Fine et al.[11]	Hepatitis A	33	M	13	Inactivated vaccines	None	20/25-2	20/20	None	6
Stangos et al. [12]	Hepatitis A and yellow fever	50	F	10	Inactivated vaccines	None	20/40	20/20	None	6
Cohen [9]	Human papilloma virus and meningococca	17	F	30	Recombinant vaccines	None	20/200	20/20	None	8
Goyal et al. [13]	Influenza	53	M	10	Undisclosed	Hepatitis B and C infection, polysubstance abuse	20/25-2	20/20	None	4
Ogino et al. [8]	Human papilloma virus (Cervarix®, Glaxo Smith Kline) 2nd dose	16	F	14	Recombinant vaccines	None	20/16	20/16	None initially, betamethasone and antihistamine later for peripheral vascular leakage and associated visual field constriction	Retinal lesions resolved at 2 months; worsening peripheral vision loss for 2 years
Abou-Samra et al. [14]	Influenza	27	F	14	Undisclosed	Stevens-Johnson syndrome, Wolff-Parkinson-White, vesicourethral reflux, mild chronic kidneydisease, endometriosis, fibroadenomas, depression with anxiety	20/25-2	Undisclosed	None	8
Yang et al. [15]	Rabies 3rd dose	33	F	14	Embryonated-egg vaccine	None	20/20	20/20	Retrobulbar triamcinolone acetonide 40 mg	Partially resolved at 8 weeks
Ng et al. [2]	Influenza (Flucelvax Quadrivalent® Seqirus)	34	M	14	Inactivated vaccines	None	20/20+2	20/16	None	4
Rabinovitch et al. [16]	COVID-19 2nd dose	39	M	5	mRNA vaccines	None	20/32	20/20	None	8
		28	F	30	mRNA vaccines	None	20/32	20/20	None	8
Xu and Shen [17]	COVID-19 1st dose	49	F	2	Inactivated vaccines	MEWDS	20/100	20/20	Oral prednisone	8
Inagawa et al. [18]	COVID-19 1st dose	30	F	6	mRNA vaccines	None	20/20	20/20	Topical corticosteroid	8
Yasuda et al. [19]	COVID-19 2nd dose	67	F	1	mRNA vaccines	None	20/100	20/25	None	2
Lin and Hsieh [20]	COVID-19 1st dose	36	F	2	Recombinant vaccines	None	20/25	20/20	None	4
Tomishige et al. [21]	COVID-19 1st dose	38	F	7	Inactivated vaccines	None	20/400	20/20	Oral prednisone	4
Smith et al. [22]	COVID-19 2nd dose	15	M	14	mRNA vaccines	None	20/100	20/20	Oral prednisone	2
		21	F	21	mRNA vaccines	None	20/60	20/20	Oral prednisone	2
Bolletta et al. [23]	COVID-19 2nd dose	53	M	28	mRNA vaccines	None	20/25	20/20	None	Undisclosed time but complete resolution
	COVID-19 1st dose	18	F	4	mRNA vaccines	None	20/66	20/20	None	Undisclosed time but complete resolution
	COVID-19 1st dose	48	M	7	mRNA vaccines	None	20/400	20/20	None	Undisclosed time but complete resolution
Alhabshan and Scales [24]	COVID-19 3rd dose	71	F	3	mRNA vaccines	Retinal tear was treated with laser barricade; hysterectomy, hypercholesterolemia	20/30	Undisclosed	None	6
Gargouri et al.[25]	COVID-19 1st dose	23	F	10	mRNA vaccines	SARS-CoV-2 infection	20/20	20/20	None	6
		40	M	7	mRNA vaccines	None	20/25	Undisclosed	None	6
N = 24	41.7% developed after receiving the second or the third dose vaccination	Mean:35.9 Median: 33.5 Range:15–71	66.7% female	Mean:11.1 Median: 8.5 Range: 1–30	91.7% of vaccines are inactive	79.2% none	Mean: 20/34 Median: 20/30 Range: 20/400–20/16	Mean: 20/20 Median: 20/20 Range: 20/25–20/16	70.8% none	Mean: 5.9 Median: 6 Range: 2–12